Oncolytics Biotech is issuing a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. The strong efficacy results from BRACELET-1 provide the foundation for a large Phase 2 study designed to support an accelerated approval. Early in 2025, the company plans to submit to the FDA a pelareorep + paclitaxel combination therapy breast cancer trial. The recently reported final BRACELET-1 study results provide clear evidence of pelareorep’s ability to improve outcomes in patients with advanced breast cancer. The company also anticipates continuing its development of pelareorep in gastrointestinal cancers. Once the master protocol has been finalized with GCAR for the pelareorep combination therapy, the company intends to approach the FDA before the end of the year.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval
- Oncolytics Biotech Nears FDA Accelerated Approval
- Oncolytics price target raised to C$3.50 from C$3 at Raymond James
- Oncolytics Phase 2 breast cancer data ‘compelling, says H.C. Wainwright
- Oncolytics Biotech’s Promising Breast Cancer Study